Pharmaceuticals
Commercializing and developing pharmaceuticals addressing large unmet needs
Improving the lives of people suffering from mental illness and substance use disorders
Developing improved pharmaceuticals based on innovative drug delivery technologies
Providing evidence-based digital therapies to improve treatment outcomes
What we do
Digital Therapeutics
Product portfolio of scientifically proven digital therapies
Mental illness & substance use disorders
Focusing on areas of great human suffering with wider societal implications
Today our thoughts go to people around the world who are suffering from MENTAL ILLNESS.
At Orexo we EMPOWER these people. Their well-being is at the HEART of what we do and understanding their needs and challenges are key for us.
In our blog we shed LIGHT on them and giving HOPE there is a road to recovery.
Key News
OCTOBER 22, 2021
Invitation to presentation of the Q3 Interim Report, November 3 at 1 pm CET
OCTOBER 18, 2021
MODIA™ paper published in the JMIR Mental Health
AUGUST 30, 2021
Synthetic opioids drive record-high surge in fatal overdoses
Orexo Social
@OrexoABpubl
22 October 2021
Last week we attended the Behavioral Healthcare’s Annual Meeting in Washington DC. Great to connect with so many be… https://t.co/p63OVHuPrE
@OrexoABpubl
20 October 2021
Look forward to commence a partnership with @just_miine_ which will allow access to our clinically proven digital t… https://t.co/5CVeKxhlsR
@OrexoABpubl
19 October 2021
We are so proud to have Dennis Urbaniak,EVP Digital Therapeutics, in a nice piece of article @Forbes where he gives… https://t.co/GILq2z2vUS
Our history
Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.
News Flow
Press Releases & News
Financial Snapshot
Group net revenues
585 MSEK
LTM1
Group EBITDA
-76 MSEK
LTM1
US Pharma segment EBIT
295 MSEK
LTM1
Cash position
680 MSEK
Q2 2021
1 Last Twelve Months, Q320-Q221, for more information about financial development Link